About TACTICAL THERAPEUTICS, INC
Tactical Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to overcome resistance in aggressive cancers, particularly glioblastoma (GBM) and other resistant solid tumors. The company's lead compound, Carboxyamidotriazole Orotate (CTO), is an oral, brain-penetrant therapy targeting calcium signaling pathways.
Development of first-in-class and best-in-class inhibitors of non-voltage-dependent calcium signalingOral therapy with a strong safety profileAbility to cross the blood-brain barrier effectivelyTargeting multiple cancer pathways simultaneouslyDesigning therapies to overcome resistance mechanismsEarly-phase oncology trial executionPharmacokinetics and tissue penetration studiesBiomarker-driven translational research
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to TACTICAL THERAPEUTICS, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.